PFT Interpretation: Real-Life Cases for Spirometry & DLCO

This section presents the complete framework for asthma severity classification and pharmacotherapy. The GINA stepwise classification system defines four steps based on daytime symptoms, nighttime awakenings, FEV1 values, and exacerbation frequency. Step 1: Infrequent symptoms, no nighttime awakenings, FEV1 >80%, no exacerbations. Step 2: More frequent symptoms, some nighttime awakenings, FEV1 60-80%, occasional exacerbations. Step 3: Daily symptoms, nighttime awakenings >1/week, FEV1 60-80%, frequent exacerbations. Step 4: Frequent activity limitation, FEV1 <60%, frequent exacerbations. Pharmacotherapy includes rescue medications (SABA like salbutamol, anticholinergics) and controller medications (inhaled corticosteroids as cornerstone, LABA, leukotriene modifiers). Overuse of SABA (>3 inhalers/month) is associated with increased hospitalizations and mortality due to receptor down-regulation. Current guidelines recommend LABA combined with inhaled corticosteroids as first-line controller therapy.

DPOC severity is classified using GOLD criteria based on FEV1/FVC ratio <0.7 after bronchodilator: GOLD 1 (mild) - FEV1 ≥80% predicted; GOLD 2 (moderate) - FEV1 50-80%; GOLD 3 (severe) - FEV1 30-50%; GOLD 4 (very severe) - FEV1 <30%. Symptom classification (A, B, E) guides treatment: Group A (low symptoms, no exacerbations) gets SABA/SAMA/LABA/LAMA; Group B (high symptoms, no exacerbations) gets LABA+LAMA; Group E (exacerbator) gets LABA+LAMA+ICS if eosinophils >300. Smoking cessation is the primary intervention for all patients.

Systematic PFT interpretation: (1) Check FEV1/FVC ratio first - <70% indicates obstructive disease, (2) If ratio normal, check FVC - <80% indicates restrictive disease, (3) If both normal, check DLCO - <75% indicates gas transfer impairment. Severity classification: Obstructive - mild (60-70%), moderate (50-60%), severe (35-50%), very severe (<35%). Restrictive - mild (TLC 65-80%), moderate (50-65%), severe (<50%). FVC helps distinguish pure obstruction from mixed disease. This systematic approach ensures accurate diagnosis and guides treatment decisions.

PFT changes correlate with ILD severity: mild disease shows FVC normal or slightly reduced, DLCO normal or slightly reduced, 6MWT distance normal or slightly reduced; moderate disease shows FVC reduced, DLCO reduced, 6MWT distance reduced; severe disease shows FVC significantly reduced, DLCO significantly reduced, 6MWT distance significantly reduced. PFT monitoring frequency depends on disease severity: baseline PFT is essential for all ILD patients; follow-up PFT every 6-12 months for stable patients; more frequent monitoring for rapidly progressive disease; PFT before treatment decisions (antifibrotic therapy, oxygen, transplantation); PFT before lung transplantation evaluation. PFT serves multiple purposes: baseline assessment for treatment planning; monitoring treatment response; prognostic assessment; guiding treatment decisions (oxygen therapy, pulmonary rehabilitation, transplantation). FVC and DLCO are the most important parameters for prognosis and treatment decisions. Regular PFT monitoring is essential for optimal ILD management.

GOLD classifies COPD severity by post-bronchodilator FEV1% predicted: Group 1 (≥80%), Group 2 (50-79%), Group 3 (30-49%), Group 4 (<30%). Treatment escalates by severity: ICS reserved for Groups 3-4 with frequent exacerbations (>2/year), significant symptoms, or eosinophil >300/μL. Core management includes smoking cessation, exposure reduction, vaccinations, lifestyle modification, stepwise pharmacotherapy, comorbidity treatment, supplemental oxygen, and pulmonary rehabilitation (underutilized). Advanced options include lung volume reduction surgery, bullectomy, bronchoscopic valves/coils, and lung transplantation (one-third of US transplants). Asthma-COPD overlap requires treating asthma first with appropriate medications.

Methacholine challenge test is performed in specialized labs only because severe bronchoconstriction can occur. It is indicated when spirometry is normal but asthma is suspected based on chronic cough, intermittent cough, or unexplained exertional dyspnea. A positive test requires a 20% or greater decrease in FEV1 after methacholine administration, compared to normal subjects who typically show only 3-7% decrease.

Bronchoprovocation testing is used when baseline lung function is normal but asthma is suspected. The patient inhales a bronchoconstrictor (methacholine), and FEV1 is measured before and after. A drop of more than 20% indicates airway hyperresponsiveness, supporting asthma diagnosis. This test is reserved for cases where baseline spirometry is normal but clinical suspicion remains high.

Bronchial provocation testing is used when baseline lung function is normal but asthma symptoms are present. The patient is given a bronchoconstrictor (like methacholine) and asked to exercise. If FEV1 drops by more than 20%, this indicates asthma. This test is useful for identifying asthma in patients with normal baseline lung function but a history of asthma symptoms. It helps diagnose asthma in cases where standard spirometry shows normal results.

Bronchoprovocation testing uses methacholine challenge to diagnose asthma by inducing bronchoconstriction in susceptible individuals. The test involves inhaling increasing concentrations of methacholine while measuring FEV1 response. A positive result is defined as a 20% or greater decrease in FEV1 from baseline. This test is particularly useful when clinical suspicion remains high despite normal spirometry results, though it carries some risk of inducing severe bronchospasm and requires careful patient selection and supervision.

Anti-inflammatory treatment response testing shows FEV1 improvement (12% increase, 200ml absolute) after anti-inflammatory therapy, confirming asthma. Exercise challenge testing requires FEV1 decrease of 15% or more (200ml absolute) to confirm exercise-induced asthma. Bronchoprovocation tests induce airway narrowing using methacholine, histamine, hypertonic saline, or mannitol. Methacholine challenge uses PC20 threshold of 16mg/m³ or lower as positive. Alternative agents require 15% FEV1 decrease. These tests assess airway hyperresponsiveness when baseline spirometry is normal.

Cardiopulmonary exercise testing (CPET) is a comprehensive stress test that evaluates both cardiac and pulmonary function simultaneously to identify the cause of unexplained dyspnea when standard tests like PFTs, chest X-rays, and stress tests are inconclusive; it assesses aerobic and anaerobic thresholds, ventilatory efficiency, oxygenation, heart rate, and pulse oximetry to determine whether shortness of breath originates from pulmonary, cardiac, deconditioning, neuromuscular, or metabolic factors.

Cardiopulmonary exercise testing (CPET) is a dynamic, non-invasive diagnostic tool that evaluates the integrated response of the cardiovascular, respiratory, and muscular systems during exercise, helping to diagnose unexplained breathlessness when conventional resting tests are inconclusive; it measures oxygen consumption (VO2), carbon dioxide production (VCO2), heart rate, ECG, and blood pressure to identify specific limitations such as cardiovascular dysfunction, ventilatory impairment, or V/Q mismatch that may not be apparent at rest.

Cardiopulmonary exercise testing (CPET) identifies the limiting factor in dyspnea: cardiac (inadequate cardiac output), pulmonary (ventilatory limitation), or metabolic. VO2 peak and oxygen pulse help differentiate causes. CPET is particularly useful for preoperative risk assessment in DPOC patients and for patients with unexplained dyspnea.

Cardiopulmonary exercise testing (CPET) is the most sophisticated diagnostic tool for complex, multifactorial, or undiagnosed dyspnea cases. It involves incremental exercise with simultaneous measurement of ventilation, gas exchange, heart rate, blood pressure, and oxygen saturation. CPET is particularly useful when patients have documented disease in both pulmonary and cardiac systems, aren't responding to initial treatments, or when the primary cause remains unclear. Interpretation distinguishes respiratory from cardiovascular limitations: respiratory patterns include reaching maximal ventilatory capacity, increased dead space ventilation, hypoxemia, or bronchospasm; cardiovascular patterns include heart rate exceeding 85% of age-predicted maximum, early anaerobic threshold, abnormal blood pressure response, O2 pulse plateauing, or ECG ischemic changes.

Cardiopulmonary exercise testing (CPET) is essential for diagnosing unexplained dyspnea by systematically evaluating three integrated systems: cardiovascular limitation (reduced oxygen pulse, early anaerobic threshold, and reduced peak VO2), ventilatory limitation (reduced breathing reserve and elevated VE/VCO2 slope >35), and pulmonary vascular disease (elevated VE/VCO2 slope >37); a systematic approach combining clinical history, resting tests, and CPET interpretation helps identify the predominant limitation and guide treatment, while distinguishing true physiological limitations from perceived breathlessness requires assessing the Borg dyspnea score, exercise capacity, breathing patterns, and considering factors like obesity and deconditioning.

PFTs are critical for surgical risk assessment, particularly lung resection: (1) Preoperative PFT identifies patients at risk for postoperative respiratory complications; (2) For lung resection, FEV1 should be above 80% of predicted for safe pneumectomy; (3) For lobectomy, FEV1 should be above 1.5L; (4) For pneumectomy, FEV1 should be above 80% of predicted; (5) Patients with FEV1 below 50% and FVC below 1.5L have high postoperative respiratory risk. PFTs also assess general surgical risk in patients with respiratory risk factors.

Pulmonary function tests (PFTs) are standardized assessments essential for thoracotomy and high-risk surgeries. They consist of three components: lung mechanics, pulmonary function, and cardiopulmonary interaction. Diagnostic uses include evaluating symptoms, occupational exposures, and drug toxicity monitoring. Prognostic applications assess disease severity progression, treatment response, and disability categorization. ACCP guidelines recommend PFTs for lung resection patients who are smokers, have unexplained dyspnea, undergo cardiac/abdominal surgery, or have uncharacterized pulmonary symptoms. Contraindications include recent MI, unstable angina, aneurysm, active TB, recent ocular surgery, and pneumothorax.

Preoperative pulmonary function assessment uses specific thresholds: abdominal surgery requires FEV1<70% predicted or <2L for complication risk; thoracic surgery requires FEV1<2L for pneumonectomy, <0.6L for segmental resection, with ratio<65% indicating high risk and ratio<50% indicating very high risk. Postoperative FEV1 prediction formula: Pre-op FEV1 × (1 - segments removed/47). If post-op FEV1>40% predicted, no/minor complications; if <40%, likely need postoperative ventilation; if <30%, non-surgical management should be considered. Additional criteria: post-op DLCO>40% and SpO2>90% on air with FEV1>40% indicates intermediate risk; both <40% indicates high risk requiring CPET. Split lung function testing identifies ventilated/perfused lung segments when DLCO and FRC are abnormal, determining whether remaining lung can adequately support the patient.

Preoperative pulmonary evaluation is essential for identifying high-risk patients and optimizing perioperative strategies. Postoperative pulmonary complications occur in 5% of surgical patients (1 in 20), including pneumonia, respiratory insufficiency, bronchospasm, atelectasis, pleural effusion, pneumothorax, and aspiration pneumonitis. Risk factors are categorized as patient-specific (age, COPD, general condition) and surgery-related (incision site, duration, emergency status). Thoracic and upper abdominal surgeries carry highest risk due to diaphragm dysfunction and pain limiting coughing. Spirometry optimizes known pulmonary disease but has limited predictive value for general surgical populations.

Pulmonary function tests (PFTs) are valuable for diagnosing respiratory conditions like asthma, tumors, and pulmonary hypertension but are not useful for surgical risk assessment; PFTs should be performed for unexplained dyspnea but not routinely before non-respiratory surgeries, and clinicians must understand that abnormal PFT results do not necessarily indicate pulmonary disease as multiple factors including age, smoking status, and non-respiratory conditions can significantly affect test results.